11.2% vs 14.9%. That is the gap between oral and injectable GLP-1 weight loss in the head-to-head data I could find. Foundayo — orforglipron, Eli Lilly's once-daily oral small-molecule GLP-1 — achieved 11.2% average weight loss at 72 weeks in the ATTAIN-1 trial. Wegovy — semaglutide, Novo Nordisk's weekly injectable biologic — achieved 14.9% at 68 weeks in the STEP 1 trial. On paper, the injectable wins. But paper is not real life. And real life is where adherence, cost, convenience, and side effects live. I built a spreadsheet to compare them. It has 47 rows, 12 columns, and one very angry conclusion.
I started this comparison because I am on Foundayo. I switched from Wegovy in April 2026 when the oral pill launched. I wanted to know if I had made a mistake. My data analyst brain does not accept "oral is easier" as a sufficient reason. I need numbers. I need efficacy curves, cost trajectories, adherence rates, side effect profiles, and quality-of-life scores. I need the whole dashboard. And I built it.
Here is what the data says. The ATTAIN-1 trial for Foundayo enrolled 3,127 adults with obesity or overweight. Three doses: 12 mg, 24 mg, 36 mg. The 36 mg dose showed 12.4% weight loss at 72 weeks. The 12 mg dose showed 9.6%. The overall average was 11.2%. The STEP 1 trial for Wegovy enrolled 1,961 adults. One dose: 2.4 mg weekly injection. Average weight loss: 14.9% at 68 weeks. The gap is 3.7 percentage points. In a 200-pound person, that is 7.4 pounds. Not trivial. But not decisive.
Calculate your BMI instantly with visual category charts and history storage.
All data stays in your browser — we never see it.The adherence data is where the story shifts. Real-world adherence to injectable GLP-1s is terrible. Industry data — leaked from pharmacy benefit managers, confirmed by published studies — shows 12-month persistence rates of 30-40% for Wegovy and Ozempic. That means 60-70% of patients stop within a year. Reasons: injection pain, nausea, supply shortages, cost, travel logistics (the drug needs refrigeration), and injection site reactions. The oral pills do not have injection barriers. They do not need refrigeration. They fit in a pocket. They can be taken anywhere. Early adherence data for Foundayo — from Eli Lilly's own monitoring and independent pharmacy analyses — shows 12-month persistence rates of 55-65%. That is a 25 percentage point improvement. And in real-world effectiveness, adherence often matters more than efficacy.
I modeled this. Patient A starts Wegovy. Efficacy: 14.9% weight loss if adherent. Adherence: 35% at 12 months. Real-world result: 5.2% weight loss. Patient B starts Foundayo. Efficacy: 11.2% weight loss if adherent. Adherence: 60% at 12 months. Real-world result: 6.7% weight loss. The less effective drug produces better real-world outcomes because more people actually take it. This is not a hypothetical. This is the central challenge of pharmacotherapy. The best drug in the world is useless if it sits in a refrigerator while the patient is on vacation.
The side effect profiles are different. Both drugs cause nausea, vomiting, diarrhea, and constipation. The injectables have higher rates of injection site reactions — 15-20% of patients report pain, redness, or swelling. The orals have higher rates of gastrointestinal side effects in the first 4-6 weeks — the pill passes through the stomach and delivers the drug locally, which irritates the gastric mucosa. My personal experience: Wegovy caused mild nausea for 3 weeks, then resolved. Foundayo caused moderate nausea for 4 weeks, then resolved. The injectable was easier to tolerate long-term. But the oral was easier to start. No needles. No clinic visits. No refrigeration. The barrier to entry was lower.
Calculate your daily calorie needs with TDEE and activity level adjustments.
All data stays in your browser — we never see it.The cost comparison is dramatic. Wegovy list price: $1,349 per month. Foundayo list price: $1,049 per month. LillyDirect cash price for Foundayo: $499 first month, $749 ongoing. Wegovy cash price through NovoCare: $650 with savings card for eligible patients. The oral is cheaper at list and at cash price. But the bigger cost advantage is manufacturing. Injectable GLP-1s are biologics. They require sterile manufacturing, cold chain distribution, and complex supply chains. Oral small molecules are pills. They can be manufactured in conventional pharmaceutical plants at a fraction of the cost. Eli Lilly's cost per dose for orforglipron is estimated at 40-60% lower than semaglutide. This cost advantage will drive pricing pressure over time. The Medicare GLP-1 Bridge program covers both at $50 per month, but the government's net cost per patient is lower for the oral.
The convenience comparison is not even close. Wegovy requires weekly injections. The pen needs refrigeration. The dose escalates over 16 weeks. Miss a dose by more than 2 days, and you need to restart the escalation. Travel requires ice packs and planning. Foundayo requires daily pills. No refrigeration. No needles. No escalation protocol. Miss a dose, take it when you remember. The daily pill fits into existing habits — morning coffee, evening brushing, whatever. The weekly injection requires a new habit. Habit formation research shows that daily habits anchor faster than weekly habits. The pill has a behavioral advantage that the injection cannot match.
The pipeline dynamics favor oral. Eli Lilly has Foundayo on the market now. They have retatrutide — the triple agonist — in Phase 3, with oral formulations in development. Novo Nordisk has CagriSema — the amylin-GLP-1 combo — in Phase 3, but it is injectable. They have an oral semaglutide (Wegovy oral) approved in December 2025, but the bioavailability is low — the pill requires high doses to achieve the same blood levels as the injection — and the efficacy is lower than the injectable. The oral market is becoming Eli Lilly's domain. Novo Nordisk is defending injectables. This is not a prediction. It is a reading of the pipeline data.
Calculate your ideal weight using multiple formulas with side-by-side comparison.
All data stays in your browser — we never see it.I brought this data to my doctor. She is a pragmatic internist who sees 25 patients a day and does not have time for my spreadsheets. She looked at the adherence data and said, "If a patient will actually take the pill, I will prescribe the pill. If they will only take the injection, I will prescribe the injection. The best drug is the one the patient takes." She was right. And she was summarizing decades of pharmacology research in one sentence. Adherence beats efficacy in real-world outcomes. Every time.
But here is the frustration. The clinical trials do not measure adherence. They measure efficacy in highly controlled, highly monitored, highly motivated populations. The STEP 1 trial provided free drugs, regular check-ins, and lifestyle counseling. The real world provides none of these. The 14.9% number is a ceiling. The 11.2% number is also a ceiling. The floor — the real-world outcome — is determined by adherence, cost, access, and side effect tolerance. And in those metrics, the oral pill is winning.
My personal data supports this. I was on Wegovy for 8 months. I lost 18 pounds — 9.5% of my starting weight. I missed 4 injections because of travel and supply issues. I stopped because of a shortage in January 2026. I switched to Foundayo in April. In 4 months, I lost 12 pounds — 6.4% of my starting weight. The rate is slightly slower. But I have not missed a single dose. I have not worried about refrigeration. I have not had to plan my travel around a weekly injection. The net result is better because the consistency is better.
The future is oral. Not because oral is more effective. Because oral is more accessible. More adherable. More scalable. The manufacturing cost advantage will drive prices down. The daily habit will drive adherence up. The lack of needles will drive acceptance up. The injectables will remain for patients who need maximum efficacy — the severe obesity cases, the patients who have failed orals. But for the mass market — the 100 million Americans with overweight and obesity — the oral pill is the right tool. It is not the most powerful tool. It is the tool that the most people will actually use.
I will keep the spreadsheet open. I will keep tracking my own data. I will keep comparing the pipeline drugs. Because the oral vs injectable debate is not just about chemistry. It is about behavior. It is about access. It is about equity. And those are the variables that determine whether a drug changes lives or just changes clinical trial results. The data is clear. The pill is not perfect. But it is here. And it is working. And that is the kind of data I can trust.
